CF Foundation President and CEO Robert J. Beall, Ph.D. testified today before the House of Representatives' Energy and Commerce Committee at a hearing entitled, “21st Century Cures: Incorporating the Patient Perspective.”
The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).
March 25, 2013
|
1 min read
Aug. 31, 2012
|
1 min read
Aug. 31, 2012
|
1 min read
Legislation Would Increase Patient and Expert Participation in FDA Review of Rare Disease Treatments
April 25, 2012
|
3 min read
The U.S. Food and Drug Administration (FDA) announced that it has approved Ultresa™ delayed-release capsules, a pancreatic enzyme replacement therapy. Ultresa (pancrelipase) is manufactured by Aptalis Pharma.
March 2, 2012
|
1 min read
New Effort Will Search for Potential Therapies Targeting the Most Common Mutation of Cystic Fibrosis
Nov. 16, 2011
|
4 min read
Oct. 20, 2011
|
2 min read
The Cystic Fibrosis Foundation's successful business model was at the center of a congressional briefing in Washington, D.C., today, which focused on strategies for jump-starting drug development for rare diseases.
June 14, 2011
|
2 min read